MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and lung inflammation resulting in a progressive decline in lung function whose principle cause is cigarette smoke. MAP3K19 is a novel kinase expressed predominantly by alveolar and interstitial macrophage...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 12; p. e0167169
Main Authors Boehme, Stefen A, Franz-Bacon, Karin, Ludka, John, DiTirro, Danielle N, Ly, Tai Wei, Bacon, Kevin B
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 09.12.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and lung inflammation resulting in a progressive decline in lung function whose principle cause is cigarette smoke. MAP3K19 is a novel kinase expressed predominantly by alveolar and interstitial macrophages and bronchial epithelial cells in the lung. We found that MAP3K19 mRNA was overexpressed in a limited sampling of lung tissue from COPD patients, and a closer examination found it to be overexpressed in bronchoalveolar macrophages from COPD patients, as well as the bronchial epithelium and inflammatory cells in the lamina propria. We further found MAP3K19 to be induced in various cell lines upon environmental stress, such as cigarette smoke, oxidative and osmotic stress. Exogenous expression of MAP3K19 in cells caused an upregulation of transcriptionally active NF-κB, and secretion of the chemokines CXCL-8, CCL-20 and CCL-7. Inhibition of MAP3K19 activity by siRNA or small molecular weight inhibitors caused a decrease in cigarette smoke-induced inflammation in various murine models, which included a decrease in pulmonary neutrophilia and KC levels. In a chronic cigarette smoke model, inhibition of MAP3K19 significantly attenuated emphysematous changes in airway parenchyma. Finally, in a viral exacerbation model, mice exposed to cigarette smoke and influenza A virus showed a decrease in pulmonary neutrophilia, pro-inflammatory cytokines and viral load upon inhibition of MAP3K19. Collectively, these results suggest that inhibition of MAP3K19 may represent a novel strategy to target COPD that promises to have a potential therapeutic benefit for patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current address: California Institute for Biomedical Research, La Jolla, CA, United States of America
Conceptualization: SAB KBB.Data curation: SAB.Formal analysis: SAB JL DDT KFB.Funding acquisition: KBB.Investigation: SAB KBB KFB JL DDT.Methodology: SAB KBB JL DDT KFB.Project administration: SAB KBB.Resources: SAB TWL JL KFB.Supervision: SAB KBB.Validation: SAB KBB JL DDT KFB.Visualization: SAB.Writing – original draft: SAB.Writing – review & editing: SAB KBB.
Current address: Department of Biology, Brandeis University, Waltham, MA, United States of America
Competing Interests: The authors Stefen A. Boehme, John Ludka, Danielle DiTirro, Tai Wei Ly and Kevin B. Bacon are currently or previously employees of Axikin Pharmaceuticals, Inc. The authors' (SAB, JL, DDT, TWL, KBB) commercial affiliation does not alter our adherence to PLOS ONE policies on data sharing and materials. The author Karin Franz-Bacon is an employee of DNA Consulting, Inc., and receives compensation in the form of salary from Axikin Pharmaceuticals, Inc. The author's (KFB) commercial affiliation does not alter our adherence to PLOS ONE policies on data sharing and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0167169